ReviewJournal of pharmacokinetics and pharmacodynamics2006
Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
Review in Journal of pharmacokinetics and pharmacodynamics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.European journal of drug metabolism and pharmacokinetics · 2018Trial
- A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.Clinical pharmacokinetics · 2013Trial
- Deciphering the Combined Effects of Hydroxysafflor Yellow A and Calycosin Through Coupled PK-PD Modeling.Biology · 2026Article
- Dynamics of spatiotemporal pharmacological models for hepatitis B virus infection under lamivudine and pegylated interferon alfa-2b therapies.BMC infectious diseases · 2026Article
- A Validated LC-MS/MS Method for the Determination of Perospirone in Human Plasma and Its Pharmacokinetic Application in Healthy Volunteers.ACS omega · 2026Article
- Article
- Mitigating antibiotic resistance from missed doses.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Introduction to Single-cell Physiologically-Based Pharmacokinetic (scPBPK) Models.bioRxiv : the preprint server for biology · 2026Article
- Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti-Infectives.ChemMedChem · 2026Review
- Article
- Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Use of a PK/PD Model to Select Cetagliptin Dosages for Patients with Type 2 Diabetes in Phase 3 Trials.Clinical pharmacokinetics · 2024Article
- A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.CPT: pharmacometrics & systems pharmacology · 2024Article
- A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials.CPT: pharmacometrics & systems pharmacology · 2024Article
- Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients.CPT: pharmacometrics & systems pharmacology · 2023Article
- Mathematical modeling of regulatory networks of intracellular processes - Aims and selected methods.Computational and structural biotechnology journal · 2023Review
- Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects.Vaccines · 2022Article
- Mathematical Modeling for an MTT Assay in Fluorine-Containing Graphene Quantum Dots.Nanomaterials (Basel, Switzerland) · 2022Article
- VCPT: pharmacometrics & systems pharmacology · 2021Article
- Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A major goal in clinical pharmacology is the quantitative prediction of drug effects. The field of pharmacokinetic-pharmacodynamic (PK/PD) modelling has made many advances from the basic concept of the dose-response relationship to extended mechanism-based models. The purpose of this article is to review, from a historical perspective, the progression of the modelling of the concentration-response relationship from the first classic models developed in the mid-1960s to some of the more sophisticated current approaches. The emphasis is on general models describing key PD relationships, such as: simple models relating drug dose or concentration in plasma to effect, biophase distribution models and in particular effect compartment models, models for indirect mechanism of action that involve primarily the modulation of endogenous factors, models for cell trafficking and transduction systems. We show the evolution of tolerance and time-variant models, non- and semi-parametric models, and briefly discuss population PK/PD modelling, together with some example of more recent and complex pharmacodynamic models for control system and nonlinear HIV-1 dynamics. We also discuss some future possible directions for PK/PD modelling, report equations for general classes of novel semi-parametric models, as well as describing two new classes, additive or set-point, of regulatory, additive feedback models in their direct and indirect action variants.
Indexed as
Identifiers
16404503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.